echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Novo Nordisk received clinical approval for oral PCSK9 inhibitor NNC0385-0434 tablets

    Novo Nordisk received clinical approval for oral PCSK9 inhibitor NNC0385-0434 tablets

    • Last Update: 2021-09-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    Text|Pharmaceutical Mission Hills

    According to the latest announcement by the Center for Drug Evaluation (CDE) of the State Drug Administration of China, Novo Nordisk has declared a Class 1 new drug NNC0385-0434 tablets, which has obtained the implied license for clinical trials.

    Screenshot source: CDE official website

    High levels of LDL-C in the blood are also called "bad" cholesterol, which can increase the risk of serious cardiovascular events in patients

    Subtilisin converting enzyme 9 (PCSK9) is a liver protease

    Based on this principle, a number of PCSK9 inhibitors have been successfully developed clinically for atherosclerotic cardiovascular disease (ASCVD), familial hypercholesterolemia, and reducing heart attack and stroke in patients with cardiovascular disease And diseases such as the risk of angina pectoris that require hospitalization

    It is worth mentioning that most of the PCSK9 inhibitors currently on the market are monoclonal antibody drugs in the form of injections

    Public information shows that Novo Nordisk is currently conducting a phase 2 clinical trial to study how NNC0385-0434 tablets can reduce cholesterol in people at high risk of heart disease or heart disease

    Reference materials:

    [1] Center for Drug Evaluation of China National Medical Products Administration.

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.